NAMS logo

NAMS NewAmsterdam Pharma Company N.V.

NASDAQ · Biotechnology · Healthcare

$19.13
-0.38 (-1.95%)

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular disease…

Market Cap: $2.29Bwww.newamsterdampharma.com

Price

$27.96-1.65%
$27.42$31.48$35.53$39.59
May 1Aug 7

Social Signal Score

42
5d
—
30d
40
2 mentions
+0.0%
60d
43
3 mentions
+0.0%
90d
43
6 mentions
+0.0%
news: 6

Analyst Ratings

11 analysts
Buyconsensus
Strong Buy 0Buy 10Hold 1Sell 0Strong Sell 0
Avg price target$53.75+181.0%
Low $45Median $54.5High $61
Current Consensus

Revenue

$19.16M
$0.00$17.24M$34.48M$51.72M
Mar 2020Sep 2026

Analyst Estimates

FY2025
$-1.54
$-1.69–$-1.20
9 analysts
FY2026
$-1.53
$-1.66–$-1.37
10 analysts
FY2027
$-1.96
$-2.70–$-1.27
10 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Michael Harvey Davidson Facp.
Sector
Healthcare
Industry
Biotechnology
Employees
100
Beta
0.10
Country
NL
Piotroski score
1 / 9 (Weak)
Altman Z-score
22.86
www.newamsterdampharma.com